Incidence and risk factors of kidney impairment on patients with COVID-19: a systematic review and meta-analysis

Qixin Yang^{1,2*}, Xiyao Yang¹

¹ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China
² Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China

Address for correspondence: Qixin Yang MD Department of Cardiovascular Medicine. Xiangya Hospital, Central South University, Xiangya Rd 87, Changsha, Hunan, China ,410008 E-mail: yangqixin@csu.edu.cn Phone: +86-152-0089-7795

DISCLOSURES

No authors have any conflicts of interest to disclose

KEYWORDS

COVID-19; SARS-CoV-2; clinical features; laboratory; acute kidney injury (AKI); kidney

dysfunction.

ABSTRACT

Background: The novel coronavirus is pandemic around the world. Several researchers have given the evidence of impacts of COVID-19 on the respiratory, cardiovascular and gastrointestinal system. Studies still have debated on kidney injury of COVID-19 patients. The purpose of the meta-analysis was to evaluate the association of kidney impairment with the development of COVID-19.

Methods: The PubMed, Embase and MedRxiv databases were searched until April 1, 2020. We extracted data from eligible studies to summarize the clinical manifestations and laboratory indexes of kidney injury on COVID-19 infection patients and further compared the prevalence of acute kidney injury (AKI) and the mean differences of three biomarkers between in ICU/severe and non-ICU/non-severe cases. Heterogeneity was evaluated using the I² method. **Results**: In the sum of 19 studies with 4375 patients were included in this analysis. The pooled prevalence of AKI, increased serum creatinine (Scr), increased blood urea nitrogen (BUN), increased D-dimer, proteinuria and hematuria in patients with COVID-19 were 7.7%, 6.6%, 6.2%, 49.8%, 42% and 30.3% respectively. Moreover, the means of Scr, BUN and D-dimer were shown 6-folds, 1.8-folds and 0.68-folds, respectively, higher in ICU/severe cases than in corresponding non-ICU/non-severe patients. The prevalence of AKI was about 17 folds higher in ICU/severe patients compared with the non-ICU/non-severe cases.

Conclusions: Overall, we assessed the incidences of the clinic and laboratory features of kidney injury in COVID-19 patients. And kidney dysfunction may be a risk factor for COVID-19 patients developing into the severe condition. In reverse, COVID-19 can also cause damage to the kidney.

INTRODUCTION

In December 2019, a group of pneumonia cases caused by an unknown virus was first reported in Wuhan, Hubei province, China^{1,2}. Those cases have similar symptoms of virus infection, including fever, fatigue, and dry cough as well as myalgia, dyspnea^{1,2}. WHO has officially named this novel coronavirus as severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) after the pathogen was isolated and identificated^{3,4}. Nowadays, this novel coronavirus is causing COVID-19 epidemic on the international scale due to its highly transmissive and contagiousness, compared with other coronavirus infection diseases including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS)⁵. As of April 21, 2020, a total of 2531804 confirmed cases involved in 185 countries and regions, and the numbers continue to rise. And SARS-CoV-2 mainly causes a series of the clinical characteristics in the respiratory system, such as asymptomatic infection, mild upper respiratory tract illness, severe acute respiratory distress syndrome, respiratory failure and even death^{1,2,6}. The pathogenic mechanism of SARS-CoV-2 is binding to membrane ACE2 for entering into pulmonary cells⁴. And ACE2 is widely distributing in several vital organs including lung, heart, kidney and intestine⁷. Apart from the respiratory symptom, SARS-CoV-2 also caused cardiovascular damage, not only led to acute cardiac injury (ACI) with an increased highsensitivity cardiac troponin I (hs-cTnI) in clinic¹. On the other hands, patients with pre-existing cardiovascular diseases (CVDs) are more likely developed into the severe condition and even contribute to highly mortality^{1,8,9}. Moreover, SARS-CoV-2 has an impact on the gastrointestinal system, bringing symptom like diarrhea with a statistically significant difference, which may be underestimated on clinical diagnosis¹⁰. Further study has proved that SARS-CoV-2 infects the gastrointestinal tract, the results of histologic and immunofluorescent staining of gastrointestinal tissues from COVID-19 patients were showed that the existence of ACE2 receptor and viral nucleocapsid protein in the cytoplasm of gastric, duodenal, and rectum glandular epithelial cell.¹¹

Therefore, we are also concerned whether SARS-CoV-2 causes kidney dysfunction and whether COVID-19 patients with kidney impairment are at a higher risk. Some clinical studies have focus attention on kidney injury of COVID-19 patients. Zhen Li et al. has shown that a large proportion of COVID-19 patients is accompanied by kidney dysfunction, including proteinuria, hematuria, increased serum creatine and blood urea nitrogen¹². Yichun Cheng also demonstrated that kidney injury is associated with in-hospital death of COVID-19 patients¹³. However, Luwen Wang thought that SARS-CoV-2 did not cause obviously kidney damage to patients¹⁴. With issue arising, a meta-analysis with large clinical samples is desperately warranted to produce a convincible result.

METHODS

Our study was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses of individual participant data (the PRISMA-IPD) statement¹⁵

Data source, search strategy and selection criteria

PubMed, EMBASE, and MedRxiv databases were applied for searching studies published from December 2019 to April 2020 in China. To identify all the articles displaying the renal injury and impairment in COVID -19, we used the following keywords or search terms alone and in combination: "novel coronavirus", "China", "HCoV", "nCoV" "Wuhan", "COVID-19"

"SARS-CoV-2", "clinical", "laboratory", "kidney", "Acute Kidney Injury", "proteinuria" and "hematuria". Detailed search strategies were illustrated in Figure 1.

Inclusion criteria are as follows:(1) comparative studies: randomized controlled trials RCTs or non-RCTs published only restricted in English; (2) patients in the studies should be confirmed to have been infected by COVID-19; (3)studies containing information about the clinical or laboratory characteristics (4) studies containing the comorbidities of kidney dysfunction and the outcome of kidney impairment. Exclusion criteria are (1) studies that less than 10 patients were included; (2) case reports, editorials, comments, non-clinical studies, reviews, studies without reliable information; (3) studies with special populations (e.g., only focused on children or severe or death cases).

Data extraction and study quality assessment

Prevalence of comorbidities and clinical manifestations of kidney damage, including AKI, proteinuria and hematuria, together with laboratory indexes of kidney impairment (confirmed by elevation of Scr, BUN and D-dimer) were extracted from the identified studies. The subgroup measure parameters were to compare the incidences of AKI and the mean differences of the three laboratory indicators among ICU and Non-ICU cases (severe and non-severe data as the second choice if ICU data was not provided). Cochrane Collaboration's tool was applied to evaluate the risk of bias.

Statistical analysis

All analyses were performed using OpenMeta Analyst (version 12.11.14) (http://www.cebm.brown.edu/openmeta/) and Review Manager (version 5.3). Forest plots were used to depict the incidences of clinical and laboratory features of kidney dysfunction of

COVID-19 patients. The odds ratio (OR, 95% confidence intervals (CI)) and mean differences (MD, 95% confidence intervals (CI)) were used to illustrate the comprehensive effects of COVID-19 occurring in ICU/severe patients and non-ICU/non-severe patients. And I² statistics were used to assess the statistical heterogeneity. The fixed-effect model was used if I² < 50% and the random effect model was used if I² \geq 50%⁸. The funnel plots were used to show the risk of publication bias.

RESULTS

Selected literature and studies characteristics

At initially, we have searched a total of 838 studies after 231 duplicate studies were identified. Following reviewed the titles and abstracts, we ruled out 772 non-clinical research, reviews, comments, case reports and studies of participants less than 10. With the remaining 66 documents, we reviewed and evaluated the whole articles with detailed information. We further excluded 47 records for multiple reasons such as lacking enough clinical information and only demonstrated the exceptional cases. In the result, we identified 19 eligible studies meeting our inclusion criteria for our meta-analysis, including 4375 COVID-19 positive patients (**Figure 1**). All of them were retrospective, descriptive observational studies including 14 single-center and 5 multiple-center studies, which were mainly conducted between December 2019 and March 2020.

The epidemiological and clinical characteristics of COVID-19 from 19 included studies were illustrated in **Table 1**. And we also described the prevalence of the complications of kidney injury on clinic and laboratory features. The majority of studies were performed in Wuhan and

other cities in China. Among all selected studies, the infected men accounted for a more substantial proportion than women and the men to women ratio was 1.2. The mean age of the participants was 52.5 years (95% CI, 49.7-55.4).

AKI and biomarkers of kidney dysfunction

Our outcome of meta-analysis for identified studies suggested that the AKI occurred 7.7% (95% CI 4.5-10.9%) in COVID-19 patients (**Figure 2A**). According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines¹⁶ and the limited clinical and laboratory information acquired from those studies, we used several indicators to display the comorbidities of kidney dysfunction. And the most prevalent laboratory indexes were increased Scr (6.6%, 95% CI 3.0-10.2%) (**Figure 2B**), increased BUN (6.2%, 95% CI 2.4-10.1%) (**Figure 2C**) and increased D-dimer (49.8%, 95% CI 35.4-64.2%) (**Figure 2D**). We included D-dimer for the reason that the elimination of D-dimer protein partially happens through kidney and high D-dimer is associated with the dysfunction of kidney¹⁷. However, the I² index ranging from 82% to 98% revealed significant heterogeneity in the evaluation of AKI, Scr, BUN and D-dimer among the included studies (P<0.001) (**Figure 2 A-D**).

Risk stratification factors for COVID-19

To identify the risk factors for critical illnesses of COVID-19 patients, we then analyzed the relevance of the AKI and the three laboratory indexes with the clinical severity through comparing the incidences of AKI and mean differences of those biomarkers between ICU/severe and non-ICU/non-severe cases. Following the results of the heterogeneity test were all shown as $I^2 < 50\%$, we applied the fixed-effect model for further investigations. For AKI, the result from 6 studies including 1813 patients showed that the AKI occurred statistically

significantly higher in ICU cases (20.3%) compared with non-ICU cases (1.3%) [OR 17.1 95%CI (9.65,29.96), Z=9.80, P<0.00001] (**Figure 2A**). In terms of laboratory results, there were considerable differences between ICU and non-ICU cases in Scr (MD=6.09 µmol/L, 95%CI 2.71-9.47, 10 studies, n=1064) (**Figure 2B**), BUN(MD=1.84µmol/L, 95%CI 1.44-2.25, 7 studies, n=701) (**Figure 2C**) and D-dimer (MD=0.68mg/L, 95%CI 0.55-0.82, 10 studies, n=1478) (**Figure 2D**). In conclusion, AKI, increased Scr, BUN and D-dimer were prominent features when patients developed into critical conditions (all P<0.001) (**Figure 2A-D**).

Clinical characteristics of kidney impairment

AKI is a risk factor of proteinuria and subsequently can be developed into chronic kidney disease(CKD)¹⁸. Here, we sought to further explore the clinical effects of kidney impairment caused by COVID-19, and we analyzed another two clinical features among COVID-19 patients. The results show that the most prevalent of kidney injury comorbidities were proteinuria (42.0%, 95%CI 30.4%-53.7%) (**Figure 3A**) and hematuria (30.3%, 95%CI 20.6%-40.1%) (**Figure 3B**) with high heterogeneity (both $I^2 > 80\%$).

Sensitivity Analysis and bias assessment

In the end, the funnel plots displayed symmetrical distributions of the effect sizes of AKI, Scr, BUN and D-dimer, and presented no obvious publication bias (**Figure 4A-D**).

DISCUSSION

The COVID-19 has affected hundreds of millions of people posing a huge healthy threaten and bring a major burden to public healthcare institutions around the world. Compared with the other two pathogenic coronaviruses family members SARS-CoV and MERS-CoV, SARS-

CoV-2 is higher contagious causing global pandemic, whereas each of which has its own clinical manifestation. Studies have been reported that SARS-CoV-2 is sharing highly 79.6% genome sequence identity as well as high molecular structure similarity with SARS-CoV^{4,19}. Therefore, SARS-CoV-2 uses ACE2 as a cellular entry receptor as SARS-CoV^{4,20}. ACE2 is highly expressed in multiple systems and tissues, mainly in the respiratory, cardiovascular, renal and gastrointestinal systems⁷. In addition to respiratory diseases and cardiac damage caused by SARS-CoV-2 through ACE2, we still need to consider the possibility of kidney effects on COVID-19 patients.

The meta-analysis was based on data from 19 studies with confirmed COVID-19 cases in China. In all cases, men were a more significant population around 55% than women, which has similar infection characteristics as MERS and SARS^{21,22}. Also, aged and people with other comorbidities, especially cardiovascular diseases, are more likely susceptible to COVID-19²³. Our meta-analysis has shown that the prevalence of AKI is approximately 7.7%, and other laboratory biomarkers reflecting renal injuries such as increased Scr, BUN and D-dimer were presented in 6.6%, 6.2%, 49.8%, respectively. Moreover, the clinical features of kidney dysfunction are even higher than cardiovascular diseases in COVID-19 patients, proteinuria is 42% and hematuria is 30.3%, while hypertension and diabetes were showed around 8% and 5% in Jing Yang's study⁹. When compared the ICU/severe and non-ICU/non-severe cases, our results have demonstrated that the AKI happened 17-folds higher in critical condition, while the incidence of acute cardiac injury was around 13-folds higher in severe disease in Bo Li's study⁸. At all, the kidney injury is more susceptibility than cardiac damage so that we should pay more attention to protecting the normal function and recovery of kidney

Due to the restriction of clinic information and most of the studies did not include in the death cases and the mortality of COVID-19, the association between kidney impairment and COVID-19-induced death was not be analyzed in our meta-analysis. We still need to follow-up those COVID-19 patients in the future, as the most relevant clinical predictors are chronic kidney disease for the death in SARS patients. Therefore, the chronic diseases community will play a critical role in the management and treatment of patients affected by this epidemic disease.

However, there are still some limitations for this meta-analysis. Firstly, due to the information missing from the literature, we hardly could include study compared the complications of kidney injury between ICU/severe and non-ICU/non-severe patients. In which cases, we did not perform sensitivity analysis and subgroup analysis for proteinuria, hematuria or uric acid. Secondly, we found that the high statistic heterogeneity in the prevalence of kidney injury analysis. The reasons are related to the study designs and significant variations among studies in the sample sizes. Thirdly, therapies under investigation for COVID-19 may have kidney side effects as lots of drugs are nephrotoxic such as aminoglycosides, ACE inhibitors and nonsteroidal anti-inflammatory drugs(NSAIDs), we are not sure whether some clinical data we got have such possibility involved, and we could not rule out the influences caused by drugs on kidney during the hospitalization.

There are some explanations for kidney injury during the COVID-19 infection episodes. Firstly, ACE-2 distributes on tubular epithelial cells of the kidney with a higher expression level compared to the lung. Thus, the kidney is also a direct aim organ attacked by SARS-CoV-2 entering into target cells through ACE-2 acting as the way in the lung. Secondly, the crosstalk relationship between lung and kidney. Kidney damage can be caused by circulating

inflammatory factors such as tumor necrosis factor (TNF)- α and interleukin (IL)-6, which are originated from pneumonia, happened in the lung. Furthermore, the local inflammatory response from injury and death renal cells will accelerate damage in the development of AKI as well as other organs^{24,25}.

On the other hand, we still need to analyze the reasons accounting for underestimating kidney impairment in COVID-19 patients in clinic. Firstly, the laboratory tests of blood chemistry analysis, including Scr and BUN, will only elevate into abnormal range when kidney lost at least 50% function because of the potent compensatory ability of kidney. From our results, we also found that the proportions of aberrant urinalysis were more than the percentage of increased plasma biomarkers. Secondly, the difficulty of precise diagnosis of AKI is another possible aspect responsible for the underrating of AKI. The detection rate of AKI mainly depends on the fluctuation of Scr and the frequency of Scr testing. And a higher incidence of AKI will be detected with adjusted denser Scr testing frequency. Therefore, more accurate strategies should be applied to the clinic when considered AKI²⁶.

In conclusion, SARS-CoV-2 causes renal injury progressing to severe AKI. At the same time, AKI is a life-threatening complication associating with a severer condition in COVID-19 patients. Therefore, we should focus more attention to kidney damage at the early stage when patients are confirmed been infected by COVID-19. There are several biomarkers can be used for monitoring the kidney function such as the level fluctuation of creatinine and urine output with the volume and hemodynamic status, and some novel indicators also should be added in for precisely stratifying the AKI severity like TIMP-2 (tissue inhibitor of metalloproteinase 2

(TIMP-2) and insulin-like growth factor binding protein 7(IGFBP7)²⁷. Moreover, to reduce the possibility of developing into critically illness and the mortality risk for COVID-19 patients, applying more protective measures and supportive medication interventions is necessary, which has a significant influence for the kidney care of patients, including but not limited to renal replacement therapies like blood filtering and purification treatments, the application of drugs with mild kidney adverse effects etc.

ACKNOWLEDGEMENTS

None.

FUNDING SOURCES

Q.Y. is supported by Chinese Government Scholarship (University Graduate Program) in

Central South University 31801-160170002.

REFERENCES

- 1. Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020; 395:497–506.
- 2. Wang D, Hu B, Hu C, et al.: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061.

3. Mahase E: Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction. BMJ 2020; 368:m1036.

- 4. Zhou P, Yang X-L, Wang X-G, et al.: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579:270–273.
- 5. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 2020; 181:281-292.e6.
- 6. Chen N, Zhou M, Dong X, et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; 395:507–513.

7. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H: Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203:631–637.

 Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y: Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol [Internet] 2020 [cited 2020 Apr 21]; Available from: http://link.springer.com/10.1007/s00392-020-01626-9

9. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y: Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and metaanalysis. International Journal of Infectious Diseases 2020; 94:91–95.

10. Liang W, Feng Z, Rao S, Xiao C, Xue X, Lin Z, Zhang Q, Qi W: Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut 2020; :gutjnl-2020-320832.

11. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H: Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology 2020; :S0016508520302821.

 Anti-2019-nCoV Volunteers, Li Z, Wu M, et al.: Caution on Kidney Dysfunctions of COVID-19 Patients [Internet]. Infectious Diseases (except HIV/AIDS), 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.08.20021212

 Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G: Kidney impairment is associated with in-hospital death of COVID-19 patients [Internet]. Nephrology, 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.18.20023242

14. Wang L, Li X, Chen H, Yan S, Li Y, Li D, Gong Z: SARS-CoV-2 infection does not significantly cause acute renal injury: an analysis of 116 hospitalized patients with COVID-19 in a single hospital, Wuhan, China [Internet]. Infectious Diseases (except HIV/AIDS), 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.19.20025288

15. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF: Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement. JAMA 2015; 313:1657.

16. Khwaja A: KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120:c179-184.

17. Cate V ten, Nagler M, Panova-Noeva M, et al.: The diagnostic performance of renal functionadjusted D-dimer testing in individuals suspected of having venous thromboembolism. Haematologica 2019; 104:e424–e427.

 Parr SK, Matheny ME, Abdel-Kader K, Greevy RA, Bian A, Fly J, Chen G, Speroff T, Hung AM, Ikizler TA, Siew ED: Acute kidney injury is a risk factor for subsequent proteinuria. Kidney International 2018; 93:460–469.

19. Lu R, Zhao X, Li J, et al.: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395:565–574.

20. Li F, Li W, Farzan M, Harrison SC: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005; 309:1864–1868.

21. Badawi A, Ryoo SG: Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. International Journal of Infectious Diseases 2016; 49:129–133.

22. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S: Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J Immunol 2017; 198:4046–4053.

23. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, Akdis CA, Gao Y: Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; :all.14238.

24. Joannidis M, Forni LG, Klein SJ, et al.: Lung–kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. Intensive Care Med 2020; 46:654–672.

25. Teixeira JP, Ambruso S, Griffin BR, Faubel S: Pulmonary Consequences of Acute Kidney Injury. Semin Nephrol 2019; 39:3–16.

26. Xu X, Nie S, Liu Z, Chen C, Xu G, Zha Y, Qian J, Liu B, Han S, Xu A, Xu X, Hou FF: Epidemiology and Clinical Correlates of AKI in Chinese Hospitalized Adults. CJASN 2015; 10:1510– 1518.

27. Pike F, Murugan R, Keener C, Palevsky PM, Vijayan A, Unruh M, Finkel K, Wen X, Kellum JA: Biomarker Enhanced Risk Prediction for Adverse Outcomes in Critically Ill Patients Receiving RRT. CJASN 2015; 10:1332–1339.

28. zhou H, Zhang Z, Fan H, et al.: Urinalysis, but not blood biochemistry, detects the early renalimpairment in patients with COVID-19 [Internet]. Urology, 2020 Apr. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.04.03.20051722

29. Zhou F, Yu T, Du R, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 395:1054–1062.

30. Cai Q, Huang D, Ou P, et al.: COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province, China [Internet]. Public and Global Health, 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.17.20024018

31. Guan W, Ni Z, Hu Y, et al.: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; :NEJMoa2002032.

32. Lu J, Hu S, Fan R, et al.: ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the early stage of outbreak in Wuhan, China [Internet]. Infectious Diseases (except HIV/AIDS), 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.20.20025510

33. quan weihe, zheng qingyou, tian jinfei, chen jun, liu zhigang, chen xiangqiu, wu tao, ji ziliang, tang jinqi, chu hao, xu haijia, zhao yong: No SARS-CoV-2 in expressed prostatic secretion of patients with coronavirus disease 2019: a descriptive multicentre study in China [Internet]. Urology, 2020 Mar. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.03.26.20044198
34. Xu Y, Xu Z, Liu X, et al.: Clinical findings in critical ill patients infected with SARS-Cov-2 in

Guangdong Province, China: a multi-center, retrospective, observational study [Internet]. Intensive Care and Critical Care Medicine, 2020 Mar. Available from:

http://medrxiv.org/lookup/doi/10.1101/2020.03.03.20030668

35. Chen G, Wu D, Guo W, et al.: Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. Journal of Clinical Investigation [Internet] 2020 [cited 2020 Mar 31]; . Available from: http://www.jci.org/articles/view/137244

Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, Yu L: Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019 [Internet]. Intensive Care and Critical Care Medicine, 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.17.20024166
 Liu J, Liu Y, Xiang P, et al.: Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage [Internet]. Infectious Diseases (except HIV/AIDS), 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.10.20021584

 lei liu, Jian-ya G: Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China [Internet]. Infectious Diseases (except HIV/AIDS), 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.20.20025536

39. Feng Z, Yu Q, Yao S, et al.: Early Prediction of Disease Progression in 2019 Novel Coronavirus Pneumonia Patients Outside Wuhan with CT and Clinical Characteristics [Internet]. Infectious Diseases (except HIV/AIDS), 2020 Feb. Available from:

http://medrxiv.org/lookup/doi/10.1101/2020.02.19.20025296

40. Lu H, Ai J, Shen Y, et al.: A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention [Internet]. Infectious Diseases (except HIV/AIDS), 2020 Feb. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.02.19.20025031

FIGURE LEGENDS

Figure 1: PRISMA flowchart of the study selection process

Figure 2: Meta-analysis of incidences of AKI and three laboratory indexes of kidney injury.

Forest plots represent the comparisons of the prevalence of AKI and mean differences (MD)

in three laboratory indicators between ICU/severe and non-ICU/non-severe cases. A, serum

creatinine (Scr, µmol/L); B, blood urea nitrogen (BUN, µmol/L); C, D-dimer(mg/L).

Figure 3: Meta-analysis of incidences of two clinical characteristics of kidney injury. A,

proteinuria; B, hematuria.

Figure 4: Funnel plots of the comparisons of AKI (A), Scr (B), BUN (C) and D-dimer (D)

between ICU/severe and non-ICU/severe patients

Table 1 Study characteristics including number, location, age, sex and Kidney impairment of

	1	Number				Kidney metabolic diseases						
Studies	Study	of	location	Mean age	Sex	AKI	Increased	Increased	Increased	Proteinuria	Hematuria	
	period	patients		(SD)	(male,%)	%	Scr %	BUN %	D-dimer %	%	%	
Zhen Li et al. ¹²	1/6/2020- 2/21/2020	193	Wuhan, Huangshi, Chongqing	56.7(15.6)	95(49%)	28	10	14	59	59	44	
Yichun Cheng et al. ¹³	1/28/2020- 2/11/2020	710	Wuhan	61.7(14.8)	374(52.7%)	3.2	15.5	-	77.7	44.01	26.9	
Haifeng Zhou et al. ²⁸	2/2/2020- 2/29/2020	178	Wuhan	47.7(19.3)	72 (40.4%)	-	0	2.8	-	34.9	28.9	
Fei Zhou et al. ²⁹	12/29/2019 -1/31/2020	191	Wuhan	56.3(15.6)	119(62%)	15	4	-	68	-	-	
Nanshan Chen et al. ⁶	1/1/2020- 1/20/2020	99	Wuhan	55.5(13.1)	67(68%)	3	-	6	36	-	-	
Chaolin Huang et al. ¹	12/16/2019 -1/2/2020	41	Wuhan	49.3(12.6)	30(73%)	7	10	-	-	-	-	
Qingxian Cai et al. ³⁰	1/11/2020- 2/6/2020	298	Shenzhen	47(20.7)	149(50%)	5.7	4.4	4	35.7	-	-	
Weijie Guan et al. ³¹	12/11/2019 -1/29/2020	1099	Nationwide	46.7(17.0)	637(58%)	0.5	1.6	-	46.4	-		
Dawei Wang et al. ²	1/1/2020- 1/28/2020	138	Wuhan	55.3(19.3)	75(54.3%)	3.6	-	-	-	-	-	
Jiatao Lu et al. ³²	1/21/2020- 2/5/2020	577	Wuhan	53.3(20)	254(44%)	-	3	-	33.5	-	-	
Jinjin Zhang et al. ²³	1/16/2020- 2/3/2020	140	Wuhan	57.2(14.8)	71(50.7%)	-	-	-	43.2	-	-	
Weihe Quan et al. ³³	2/25/2020- 3/13/2020	18	Shenzhen, Wuhan	60.3(15.3)	NA	-	-	-	-	22.2	16.7	
Yonghao Xu et al. ³⁴	2/28/2020	45	Guangdong	56.7(15.4)	29(64.4%)	15.6	-	-	-	-	-	
Guang Chen et al. ³⁵	12/19/2019 -1/27/2020	21	Wuhan	57(11.1)	17(81%)	-	-	-	-	-	-	
Yanli Liu et al. ³⁶	1/2/2020- 2/1/2020	109	Wuhan	54.7(17.0)	59(54.1%)	-	-	-	-	-	-	
Jingyuan Liu et al. ³⁷	1/13/2020- 1/31/2020	61	Beijing	42.3(15.7)	31(50.8%)	-	-	-	-	-	-	
Lei Liu et al. ³⁸	1/11/2020- 2/6/2020	51	Chongqing	43.3(12.6)	32(63%)	-	_	_	-	-	-	
Zhichao Feng et al. ³⁹	1/17/2020- 2/1/2020	141	Hunan	44.3(15.3)	72(51.1%)	-	-	-	-	-	-	

patients of the 19 included studies

Hongzhou Lu et al.40	1/20/20-	265	Shanghai	NA	NA	-	_	_	_	_	
Hongzhoù Eu et al.	2/19/2020	205	Shanghai	11A	na -						

AKI, acute kidney injury; Scr serum creatinine; BUN blood urea nitrogen.

Figure 1






Figure 2

A Acute kidney injury



	ICU	I	Non-	ICU	Odds Ratio			Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl		M-H, Fixed, 95% Cl
Chaolin Huang et al.	3	13	0	28	4.3%	19.00 [0.90, 399.79]		
Dawei Wang et al.	3	36	2	102	16.7%	4.55 [0.73, 28.39]		
Qingxian Cai et al.	13	58	4	240	21.0%	17.04 [5.32, 54.65]		
Weijie Guan et al.	5	173	1	926	5.3%	27.53 [3.20, 237.12]		
Yonghao Xu et al.	7	20	0	24	5.1%	27.22 [1.44, 514.31]		
Zhen Li et al.	43	65	12	128	47.6%	18.89 [8.61, 41.45]		
Total (95% CI)		365		1448	100.0%	17.01 [9.65, 29.96]		•
Total events	74		19					
Heterogeneity. Chi ² =	2.36, df	= 5 (P	= 0.80);	$ ^2 = 0\%$	6		0.01	0,1 1 10 100
Test for overall effect:	Z = 9.80) (P < C).00001)				0.01	Lower Incidence[ICU] Lower Incidence[Non–ICU]

B Serum creatinine



		ICU		N	ion-ICU			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Chaolin Huang et al.	74.9	29.333	13	71.8	20.1481	28	3.7%	3.10 [-14.51, 20.71]	
Dawei Wang et al.	84	29.63	36	71	19.259	102	10.6%	13.00 [2.62, 23.38]	
Guang Chen et al.	80.3	17.7778	11	73.6	13.111	10	6.5%	6.70 [-6.58, 19.98]	_+
Hongzhou Lu et al	75.3	28.5185	22	63.333	17.3333	243	7.8%	11.97 [-0.15, 24.08]	
Jingyuan Liu et al.	65.33	22.22	17	57.12	22.3	44	7.4%	8.21 [-4.24, 20.66]	+
Lei Liu et al.	61.7	13.333	7	69	14.074	44	10.0%	-7.30 [-18.02, 3.42]	
Yanli Liu et al.	68.3	20.7407	53	65.333	20.7407	56	18.9%	2.97 [-4.82, 10.76]	
Yonghao Xu et al.	84.5	40.1481	20	65	18.963	24	3.1%	19.50 [0.34, 38.66]	
Zhen Li et al.	72.3	25.1852	65	65.7	19.2593	128	23.5%	6.60 [-0.37, 13.57]	⊢ ∎−
Zhichao Feng et al.	78.233	22.7407	15	70.9	8.5926	126	8.5%	7.33 [-4.27, 18.94]	+
Total (95% CI)			259			805	100.0%	6.09 [2.71, 9.47]	•
Heterogeneity. Chi ² =	11.40, dt	'= 9 (P = 1	0.25); İ	² = 21%					-100 -50 0 50 100
Test for overall effect:	Z = 3.53	(P = 0.00	04)						-100 -50 0 50 100 Lower Incidence[ICU] Lower Incidence[Non-ICU]

C Blood urea nitrogen


Studies	Estimate (95% C.I.)	Ev/Trt		
Zhen Li et al. 2020 Nanshan Cheng et al. 2020 Qingxian Cai et al. 2020 Haifeng Zhou et al. 2020	0.140 (0.091, 0.189) 0.061 (0.014, 0.108) 0.040 (0.018, 0.063) 0.028 (0.004, 0.052)	6/99		
Overall (I^2=82 % , P< 0.001)	0.062 (0.024, 0.101)	50/768		
		0.05	0.1 Proportion	0.15

		ICU		N	on-ICU			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Dawei Wang et al.	6.6	3.9259	36	4.067	1.4815	102	9.5%	2.53 [1.22, 3.85]	
Guang Chen et al.	6.8	2.8888	11	4.067	1.037	10	4.9%	2.73 [0.91, 4.56]	
Jingyuan Liu et al.	5.1	1.8519	17	4.2	1.1851	44	18.3%	0.90 [-0.05, 1.85]	
Lei Liu et al.	4.967	2.0741	7	4.267	1.8519	44	6.2%	0.70 [-0.93, 2.33]	
Weiliang Cao et al.	6.06	13.03	21	5.4	9.83	107	0.5%	0.66 [-5.22, 6.54]	
Yanli Liu et al.	5.533	2.2963	53	3.7333	1.4074	56	31.7%	1.80 [1.08, 2.52]	
Zhen Li et al.	6.37	2.8888	65	4	1.5481	128	29.0%	2.37 [1.62, 3.12]	
Total (95% CI)			210			491	100.0%	1.84 [1.44, 2.25]	•
Heterogeneity: Chi ² = Test for overall effect		•						H	-10 -5 0 5 1

Lower Incidence[ICU] Lower Incidence[Non-ICU]

D D-dimer

Studies	Estimate (95% C.I.)	Ev/Trt
Zhen Li et al. 2020	0.588 (0.516, 0.659)	107/182
Weijie Guang et al. 2020	0.464 (0.423, 0.506)	260/560
Fei Zhou et al. 2020	0.680 (0.611, 0.750)	117/172
Nanshan Chen et al. 2020	0.364 (0.269, 0.458)	36/99
Yichun Cheng et al. 2020	0.778 (0.747, 0.810)	520/668
Qingxian Cai et al. 2020	0.332 (0.279, 0.386)	99/298
Jiatao Lu et al. 2020	0.335 (0.285, 0.385)	115/343
Jinjin Zhang et al. 2020	0.432 (0.324, 0.540)	35/81




		ICU		No	on-ICU			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Chaolin Huang et al.	5.8	10.222	13	0.5333	0.3704	28	0.1%	5.27 [-0.29, 10.83]	
Dawei Wang et al.	0.643	0.8393	36	0.184	0.1363	102	23.3%	0.46 [0.18, 0.73]	-
Guang Chen et al.	7.3	13.4074	11	0.333	0.0741	10	0.0%	6.97 [-0.96, 14.89]	
Hongzhou Lu et al.	1.6	2.2222	22	0.463	0.3259	243	2.0%	1.14 [0.21, 2.07]	
Jiatao Lu et al.	1.0333	1.4815	70	0.3333	0.4444	211	14.3%	0.70 [0.35, 1.05]	+
Jinjin Zhang et al.	1	1.6296	38	0.2	0.1481	43	6.5%	0.80 [0.28, 1.32]	
Lei Liu et al.	0.76	0.8296	7	0.3067	0.2074	44	4.6%	0.45 [-0.16, 1.07]	
Qingxian Cai et al.	1.1417	1.0259	58	0.3733	0.2	240	25.2%	0.77 [0.50, 1.03]	· · · · · · · · · · · · · · · · · · ·
Yanli Liu et al.	1.105	1.063	53	0.42333	0.2963	56	20.1%	0.68 [0.39, 0.98]	•
Zhen Li et al.	1.887	2.7851	65	0.73	0.6815	128	3.7%	1.16 [0.47, 1.84]	
Total (95% CI)			373			1105	100.0%	0.68 [0.55, 0.82]	•
Heterogeneity. Chi ² = Test for overall effect:				2 = 21%				_	-10 -5 0 5 10 Lower Incidence[ICU] Lower Incidence[Non-ICU]

Figure 3

A Proteinuria

Studies		Estir	nate (95	% C.I.)	Ev/Trt
Zhen Li et al. 2020)	0.589	(0.504,	0.674)	76/129
Yichun Cheng et a	al. 2020	0.440	(0.394,	0.486)	195/443
Weihe Quan et al.	2020	0.222	(0.030,	0.414)	4/18
Haifeng Zhou et a	I. 2020	0.349	(0.247,	0.452)	29/83
Overall (I^2=84	% , P< 0.001)	0.420	(0.304,	0.537)	304/673



B Hematuria

Studies	Estimate (95% C.I.)	Ev/Trt
Zhen Li etal. 2020 Yichun Cheng et al. 2020 Weihe Quan et al. 2020 Haifeng Zhou et al. 2020	0.442 (0.356, 0.528) 0.269 (0.227, 0.310) 0.167 (0.000, 0.339) 0.289 (0.192, 0.387)	3/18
Overall (I^2=80 % , P=0.002)	0.303 (0.206, 0.401)	203/673




Figure 4

